Skip to main content
. 2021 Jul 21;11:691762. doi: 10.3389/fonc.2021.691762

Figure 4.

Figure 4

HBO therapy inhibits tumorigenesis in vivo in a Pfkp-dependent manner. Three cohorts were created in Lewis lung carcinoma (LLC) mice: (i) normoxic (NormOx) controls (n = 6), (ii) hyperbaric oxygen (HBO) therapy only (n = 6), and (iii) HBO therapy + pLAS.Pfkp (n = 6). (A) Representative images of hematoxylin and eosin (H&E)-stained whole lung sections (top) and higher-magnification lung sections (×400) (bottom). Scale bar = 100 μm. (B) Immunoblotting validation of Hif-1α and Pfkp. (C) LLC tumor counts and (D) mean LLC tumor volumes in each cohort. (E) Representative immunofluorescent images (×200) of Ki-67 (green)/Hoechst 33342 (blue) staining in LLC tumor sections and associated quantification of Ki-67+ cell counts per mm2 for each cohort. Scale bar = 100 μm. (F) Representative immunohistochemistry of Hif-1α, Pfkp, and p-β-catenin (S552) in LLC tumor sections (×100). Scale bar = 10 μm. (G) Immunoblotting of p-β-catenin (S552), E-cadherin, N-cadherin, and vimentin in LLC tumors. Data represented as means ± SDs. *P < 0.05, **P < 0.01 [one-way ANOVA].